– Bloomberg
Wells Fargo Downgrades Apellis Pharmaceuticals to Equal-Weight, Announces $58 Price Target
Wells Fargo analyst Derek Archila downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Overweight to Equal-Weight and announces $58 price target.